Additional file 2: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer pat…

2019

Thirty-five differentially methylated CpGs between responders and non-responders group selected from 450k array (delta value ≥ 0.2) corresponding to 23 genes located in promoter and island/shore (PPT 172 kb)

Additional file 3: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer pat…

2019

Eleven differentially methylated CpGs, corresponding to 11 genes, showed significant methylation differences between non-responder and responder patients: 6 genes (LOC641518; LEF1; HOXA5; EVC2; CDKL2; TLX3) presented a methylation increase in non-responders group vs responders, and 5 genes (ZFHX4; LOC100192378; FERD3L; CHL1; TRIP10) decreased methylation level in non-responder patients compared to those who responded to NAC treatment (PPT 225 kb)

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

2021

Anàlisi de seqüències d'ADN; Subtipus PAM50; Genètica molecular Análisis de secuencias de ADN; Subtipo PAM50; Genética molecular DNA sequence analyses; PAM50 subtype; Molecular genetic Background: The SOLTI-1301 AGATA study aimed to assess the feasibility of a multi-institutional molecular screening program to better characterize the genomic landscape of advanced breast cancer (ABC) and to facilitate patient access to matched-targeted therapies in Spain. Methods: DNA sequencing of 74 cancer-related genes was performed using FFPE tumor samples in three different laboratories with three different gene panels. A multidisciplinary advisory board prospectively recommended potential targeted trea…

MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma

2020

Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial-mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) is a master regulator of controlling the stem cell differentiation and the cell proliferation processes. We aim to evaluate the implication of miR-33b in the EMT pathway in HER2+ breast cancer (BC) and to analyze the role of EZH2 in this process as well as the interaction between them. miR-33b is downregulated in HER2+ BC cells vs healthy controls, where EZH2 has an opposite expression in vitro and in patients' samples. The upregulation of miR-33b suppressed proliferatio…

Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level

2018

The system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, modulates the role of hormones in the genesis and progression of breast tumors. We investigated whether the expression of RANK was related with clinicopathological features of primary endometrial tumors. Immunohistochemistry was used in an endometrial cancer tissue array containing samples from 36 tumors. The amount of RANK mRNA was examined in a tissue scan cDNA array containing cDNA from 40 tumors. Normal endometrium was examined for comparison. Immunohistochemical analyses showed that RANK expression was higher in malignant than in normal endometrium (p &lt

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer

2021

Simple Summary Breast cancer diagnosis at the initial stage of the disease considerably improves prognosis and survival rates. This retrospective study aimed to develop and validate a plasma microRNA signature as a non-invasive biomarker for early-stage breast cancer diagnosis. We confirmed in a testing cohort of 54 BC patients and 89 healthy volunteers the value of a signature based on miR-30b and miR-99a levels in plasma samples for stage I breast cancer detection. Furthermore, our results were blindly validated in a second cohort of 74 breast cancer and 74 healthy samples. The proposed microRNA signature presented high value as a fast, cost-effective, and non-invasive biomarker for early…

Sentinel lymph node BIOPSY after neoadjuvant therapy in breast cancer patients with lymph node involvement at diagnosis. Could wire localization of c…

2021

Abstract Introduction Sentinel lymph node biopsy (SLNB) after neoadjuvant therapy (NAT) in node-positive (N+) breast cancer patients at diagnosis remains a controversial issue, with no consensus on implementation or safety. Objectives We sought to assess the accuracy of SLNB after NAT in biopsy-proven N+ cases at diagnosis and the efficacy and accuracy of wire localization of the clipped node to improve results. Material and methods A cross-sectional diagnostic technique validation study in N+ patients following NAT was performed. The biopsy-proven affected lymph node was clipped at diagnosis. SLNB and axillary lymph node dissection (ALND) were performed in cases of clinical-radiological ly…

Aurora kinases in ovarian cancer

2020

Aurora kinases (AURK) are key regulators of the mitotic spindle formation. AURK is frequently overexpressed in ovarian cancer and this overexpression has been frequently associated with prognosis in these tumours. Interestingly, AURK have been shown to interact with DNA repair mechanisms and other cell cycle regulators. These functions have brought light to Aurora family as a potential target for anticancer therapy. In the last years, two clinical trials with different AURK inhibitors have shown activity in epithelial and clear-cell ovarian cancer. Although there is a lack of predictive factors of AURK inhibition activity, recent trials have identified some candidates. This review will focu…

HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women

2020

Background: Breast cancer in very young women (BCVY) defined as &lt

Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology

2016

Somatic mutation analysis represents a useful tool in selecting personalized therapy. The aim of our study was to determine the presence of common genetic events affecting actionable oncogenes using a MassARRAY technology in patients with advanced solid tumors who were potential candidates for target-based therapies. The analysis of 238 mutations across 19 oncogenes was performed in 197 formalin-fixed paraffin-embedded samples of different tumors using the OncoCarta Panel v1.0 (Sequenom Hamburg, Germany). Of the 197 specimens, 97 (49.2%) presented at least one mutation. Forty-nine different oncogenic mutations in 16 genes were detected. Mutations in KRAS and PIK3CA were detected in 40/97 (4…

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

2019

AbstractBackgroundNeoadjuvant treatment is increasingly one of the preferred therapeutic options for early breast cancer and may have some unique outcomes, such as identifying predictive and prognostic factors of response or increasing the knowledge of individual tumor biology.DesignA panel of experts from different specialties reviewed published clinical studies on the neoadjuvant management of breast cancer. Recommendations were made that emphasized the clinical multidisciplinary management and the investigational leverage in early breast cancer.ResultsNeoadjuvant therapy has equivalent efficacy to adjuvant therapy, and it has some additional benefits that include increasing breast conser…

Differential expression of receptor activator of nuclear factor kappa B in healthy endometrium, ovarian endometrioma, and endometrioid ovarian cancer

2019

Additional file 1: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer pat…

2019

List of all the biological processes enriched for the 71 differentially methylated genes between responder and non-responder patients according to the Gene Ontology analysis (DOCX 32 kb)

Additional file 5: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer pat…

2019

Representation of the pathway interaction network of FERD3L and TRIP10 with other genes using Pathway Commons. FERD3L and TRIP10 are able to interact with different genes that have shown to be implicated in cancer drug resistance (PPT 452 kb)

Additional file 4: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer pat…

2019

CpGs studied by pyrosequencing in the DC and in the VC to validate methylation in the candidate genes identified in the 450k array (Illumina). In bold, CpGs from 450k array. Normal type, consecutive CpGs (PPT 140 kb)

Additional file 6: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer pat…

2019

Mean differences in methylation levels according to clinicopathological prognostic factors in both cohorts (DC+VC). cT, clinical tumor size; cN, clinical nodule affectation (PPTX 48 kb)

Additional file 8: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer pat…

2019

Sequence of primers used by pyrosequencing in the validation assay of candidate genes obtained from 450k array (PPT 143 kb)

Additional file 7: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer pat…

2019

Clinical inclusion and exclusion criteria followed to select TNBC patients for the methylation study (PPT 89 kb)